Clinical diagnostics company Envision Sciences has appointed Scott Richards as its new chief executive officer.
Envision is developing and commercialising a pipeline of novel biomarker-based cancer diagnostic and prognostic tests in tissue and blood.
Mr Richards has over 35 years of experience in the global pharmaceutical industry, leading significant commercial-stage enterprises in Australia, Europe and the US.
Most recently, over ten years, he led the transition of the ASX-listed Mayne Pharma Group from a small Australian micro-cap to an integrated specialty pharmaceutical company with substantial operations in the United States in generic and branded medicines, contract development and manufacturing services.
Envision Sciences board director and majority shareholder John Higgins said, “We welcome Scott to the company at such a pivotal juncture. Scott is a highly experienced life sciences executive who brings strong leadership and deep operational experience in sales and marketing, business development, product development and manufacturing/supply chain, particularly in our critical United States markets.”
Mr Richards said, “I am delighted to be part of Envision Sciences next phase of growth, creating value for all its stakeholders. I am impressed with the world-class technology behind the company’s products and pipeline, together with the passion of the management team. Envision has a strong mix of near term opportunities with the commercialisation of our novel prostate cancer test in the United States, together with development of novel blood-based diagnostic tests for a variety of cancers. I look forward to leading a company whose mission is to significantly improve outcomes for patients with prostate and other cancers.”
Mr Peter Pursey, Envision’s CEO since 2017, will remain as Executive Chairman. Mr Pursey, as a founding shareholder, director and CEO of Envision Sciences, has taken Envision’s prostate cancer tissue-based biomarker test from concept to commercial launch in the US in 2023 as well as developing a strong pipeline of new diagnostic products.
